Skip to Main Content
Advertisement intended for health care professionals
Open Menu
Close
ASH
Open Menu
ASH Home
Open External Link
ASH Store
Open External Link
Advocacy
Open External Link
Education
Open External Link
Meetings
Open External Link
Publications
Open External Link
Research
Open External Link
ASH Clinical News
ASH Image Bank
Open External Link
ASH News Daily
ASH-SAP
Blood Journals
Open Menu
Blood
Blood Advances
Blood Global Hematology
Blood Immunology & Cellular Therapy
Blood Neoplasia
Blood Red Cells & Iron
Blood Vessels, Thrombosis & Hemostasis
Hematology
The Hematologist
International
Open Menu
Blood Chinese Edition
Open External Link
Blood Italian Edition
Open External Link
Blood Latin America Edition
Open External Link
Blood Spanish Edition
Open External Link
Cart
User Tools Dropdown
Cart
Sign In
Open Menu
Search Dropdown Menu
header search
search input
Search input auto suggest
filter your search
All Content
All Journals
Blood
Search
Toggle Menu
Menu
Issues
Open Menu
Current Issue
All Issues
First edition
Abstracts
Open Menu
2024 Annual Meeting
2024 Late Breaking
2023 Annual Meeting
2023 Late Breaking
2022 Annual Meeting
2022 Late Breaking
2021 Annual Meeting
2020 Annual Meeting
2020 Late Breaking
All Meeting Abstracts
Collections
Open Menu
Blood Cover Contest
Blood Podcast
Collections
Special Collections
Multimedia
Author Center
Open Menu
Alerts
Author Guide
Style Guide
Submit
Open External Link
Why Submit to Blood?
About
Open Menu
About Blood
Alerts
Blood Classifieds
Copyright
Editorial Board
Publications Staff
Public Access
Subscriptions
Skip Nav Destination
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
Blood
(2023) 141 (14): 1675–1684.
Currently there are no citedby results. Try again later.
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal
Advertisement intended for health care professionals
close advertisement
